International Immunosuppression Transplant Skin Cancer Collaborative Biennial Retreat

摘要 国际免疫抑制移植皮肤癌合作组织（ITSCCC）举办了一个独特的两年一度的 科学务虚会，汇集了来自世界各地的专家临床医生和研究人员， 致力于照顾免疫抑制患者的侵袭性皮肤癌，影响功能， 生存[1-3]在美国，有风险的人群包括超过30万患有实体器官衰竭的患者。 移植，20万人患有恶性血液病，110万人暴露于人类 免疫缺陷（HIV）病毒。[4]随着沿着的35，000例移植手术， 预计2020年将有8万例新的淋巴瘤诊断。ITSCC双年科学务虚会吸引了专家 来自不同的领域，包括皮肤病学，显微外科和皮肤肿瘤学，移植手术， 肾脏病学、肝病学、心脏病学、放射肿瘤学、内科肿瘤学、肿瘤外科学、耳鼻喉科 以及在农村静修中心进行整形手术，以促进自由和迅速的信息交流。独特的 环境，没有传统的筒仓，允许设计稳健的试验，开发基于证据的 指导方针，并创造机会，以促进最先进的护理免疫抑制患者 患有侵袭性皮肤癌 ITSCC将通过3个具体目标推进研究和临床护理：（1）促进整合合作 基础和临床研究，以提高免疫抑制患者的护理质量与侵略性皮肤 癌症;（2）开发新的和更有效的方法来教育患者，科学家，初级保健医生和 免疫抑制患者的独特需求和临床护理问题的专家医生， 侵袭性皮肤癌;（3）制定和传播敏感的筛查标准，以确定最高风险 个人在最早的时间点，以促进实施有效的策略，以防止侵略性皮肤 免疫抑制患者的癌症。 我们将通过传统和创新的格式相结合来实现这些目标。撤退将包括 传统的会议包括简短的发言和随后的讨论。我们还将包括目标导向的 工作组会议致力于制定或修订护理指南和制定临床 试验和多中心研究。我们预计将有40名与会者，包括为学生预留的10个名额， 居民，研究员，或年轻的研究人员，以确保组织的进一步发展， 实现长期目标。我们将通过出版会议记录来传播我们的进展 正如我们过去所做的那样，并通过继续参加包括美国社会发展协会在内的全国性会议， 移植（AST），美国皮肤病学会（AAD），美国莫氏外科学院（ACMS） 皮肤病研究学会（Society for Investigative Dermatology，SID）

Abstract The International immunosuppression Transplant Skin Cancer Collaborative (ITSCCC) hosts a unique biennial scientific retreat that brings together expert clinicians and investigators from around the world whom are dedicated to caring for immunosuppressed patients with aggressive skin cancers that impact function and survival.[1-3] The population at risk in the United States includes over 300,000 patients with solid organ transplants, 200,000 with hematologic malignancies and 1.1 million who have been exposed to human immunodeficiency (HIV) virus.[4] The numbers of vulnerable will grow with 35,000 transplants expected along with 80,000 new lymphoma diagnoses expected in 2020. The ITSCC Biennial Scientific Retreat draws experts from diverse fields including dermatology, micrographic surgery and dermatologic oncology, transplant surgery, nephrology, hepatology, cardiology, radiation oncology, medical oncology, oncologic surgery, otolaryngology and plastic surgery in a rural retreat center facilitating free and rapid exchange of information. The unique environment, absent conventional silos, allows for design of robust trials, development of evidence-based guidelines and creates the opportunity to advance the state of the art of care for immune suppressed patients with aggressive skin cancer. ITSCC will advance research and clinical care through 3 specific aims: (1) Facilitate collaboration in integration of basic and clinical research to improve the quality of care of immune suppressed patients with aggressive skin cancer; (2) Develop novel and more effective means to educate patients, scientists, primary care doctors and specialist physicians on the unique needs and clinical care issues in immune suppressed patients with aggressive skin cancer; (3) Develop and disseminate sensitive screening criteria to identify highest risk individuals at earliest time point to facilitate implementation of effective strategies to prevent aggressive skin cancer in immune suppressed patients. We will achieve these aims through combination of traditional and innovative formatting. The Retreat will include traditional sessions comprised of short presentations followed by discussion. We will also include goal-directed work group sessions dedicated to development of or revision of guidelines of care and development of clinical trials and multicenter research studies. We expect 40 attendees including 10 spaces reserved for students, residents, fellows, or young investigators to insure the further growth development of the organization and achievement of long-term goals. We will disseminate our progress through publication of meeting proceedings as we have in the past and through continued presence at national meetings including the American Society for Transplantation (AST), American Academy of Dermatology (AAD), American College of Mohs Surgery (ACMS) and Society for Investigative Dermatology (SID).